Genomic profiling from initial assessment to detection of measurable residual disease (MRD): how NGS can rapidly deliver key insights for myeloid neoplasms
sponsored by Thermo Fisher Scientific
July 27, 2022 - 08:00AM PDT
Myeloid neoplasms are a heterogeneous group of blood and bone marrow-based disorders, primarily including myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and acute myeloid leukemia (AML).
Comprehensive molecular analysis is critical for characterizing myeloid samples, understanding disease pathology, detecting residual disease mutations, and potentially informing risk-adapted therapeutic strategies.
Next-generation sequencing (NGS) is a transformative molecular testing technology that rapidly and simultaneously analyzes multiple genetic biomarkers, providing a comprehensive genomic profile from a single test.
During this presentation, Dr. Bevan Tandon of Pathline Labs will review ongoing studies in his laboratory using the Oncomine Myeloid Assay GX, an NGS-based test capable of delivering results in just 1-2 days.
He will also share his experience with the upcoming Oncomine Myeloid MRD Assay (RUO), a highly sensitive NGS test for measurable residual disease (MRD) assesment that can identify mutations occurring at very low frequencies. Dr. Tandon will share recent analytical data from his team and offer his perspective on the value of NGS in hematopathology studies.
Webinar Learning Objectives:
- The latest advancements in NGS for molecular testing of myeloid neoplasms
- How genomic profiling can provide deep insight for the assessment myeloid samples
- How NGS can benefit myeloid MRD analysis
